PECULIARITIES OF NEPHROPROTECTIVE EFFECT OF SULODEXIDE IN PATIENTS WITH DIABETIC NEPHROPATHY
Abstract
Introduction. Monocyte chemoattractant protein type 1 (MCP-1) and plasminogen activator inhibitor type 1 (PAI-1) play a key role in inflammation, fibrosis and progression of renal dysfunction. Sulodexide advantages in vascular pathology treatment were proved by clinical trials, however, its efficiency in diabetic nephropathy (DN) was investigated insufficiently.
The aim of the present work – to study the influence of sulodexide on clinical and laboratory parametres, MCP-1 and PAI-1 levels in blood plasma of patients with DN.
Materials and methods. 76 type 2 diabetic patients with different stages of DN were observed. 44 patients received basic therapy with anti-diabetic drugs and ACE- inhibitors, 32 patients in addition to basic therapy were treated with sulodexide in a daily dose 600 LU. Concentrations of MCP-1 and PAI-1 in blood plasma were determined using immunoassay kits.
Results. In patients with DN when compared with healthy controls MCP-1 and RAI-1 levels in blood plasma significantly increased already at initial stages of the disease. Such changes may promote a development of inflammatory and fibrotic processes in kidneys. Progression of the disease was accompanied by more essential growth of MCP-1 and RAI-1 in DN patients with expressed clinical manifestations of kidney injury. Sulodexide treatment in patients with DN resulted in essential decrease of inflammatory and fibrotic markers and had positive effect on urinary protein excretion.
Conclusions. Glicosaminoglycans, in particular, sulodexide, is effective in complex treatment of patients with DN.
Downloads
References
Вплив сулодексиду на рівень цитокінів в сироватці крові у хворих на діабетичну нефропатію та хронічну хворобу нирок ІІ-ІІІ стадії / Лобода О. М., Дудар І. О., Дріянська В. Є. та ін. // Український журнал нефрології та діалізу. – 2009. – №2 (22). – С. 23-26.
Влияние гликозаминогликанов на течение диабетической нефропатии на стадии микроальбуминурии у больных сахарным диабетом 2 типа / Семенова И.В., Чугунова Л.А., Ильин А.В. [и др.] // Сахарный диабет. – 2010. – №2. – C. 34-39.
Eddy A. A. Progression in chronic kidney disease / Eddy A. A. // Adv Chronic Kidney Dis. – 2010. – Vol. 12. – P. 353–365.
Gaddi A. V. Nephroprotective action of glycosaminoglycans: why the pharmacological properties of sulodexide might be reconsidered / Gaddi A. V, Cicero A. F., Gambaro G. // International Journal of Nephrology and Renovascular Disease. – 2010. – Vol. 3. – Р. 99–105.
Huang Y. PAI-1 as a target in kidney disease. / Huang Y., Noble N.A. // Curr Drug Targets. 2007 – Vol. 8, № 9. –P.1007-1015.
Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: The Di.N.A.S. randomized trial / Gambaro G., Kinalska I., Oksa A. [et al] // J. Am. Soc. Nephrol. – 2002. – Vol.13. – P. 1615– 1625.
Plasminogen activator inhibitor-1 deficiency retards diabetic nephropathy. / Nicholas S.B., Aguiniga E., Ren Y. [et al] // Kidney Int. – 2005. - Vol. 67, № 4. – P. 1297-1307.
Sulodexide suppresses inflammation in human endothelial cells and prevents glucose cytotoxicity / Ciszewicz M., Polubinska A., Antoniewicz A. [et al] // Transl Res. – 2009. – Vol. 153, N. 3. – P. 118–123.
Targeting the MCP-1/CCR2 System in diabetic kidney disease / Giunti S., Barutta F., Perin P.C., Gruden G. // Curr Vasc Pharmacol. – 2010. - Vol.8(6). – P. 849- 860.
Tesch G. H. MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy / Tesch G. H. // Am J Physiol Renal Physiol. – 2008. - Vol.294. – P. 697–701.
